Bone Metastasis Diagnosis
Bone Metastasis Diagnosis
The diagnosis of bone metastasis has two parts. The first is showing that a deposit in bone contains the original cancer's cells, or — in a patient with a known cancer and typical imaging — that the picture is characteristic enough to act on. The second is mapping how much bone is involved and where, since that decides whether the treatment is systemic, local, or both. Most of the work is done by imaging and by the pathology that already exists; a biopsy of the bone is needed only where the answer would change what is done.
The scans, and what each one answers
No single scan answers every question, and the choice between them follows what is being asked. In practice the scans are complementary, and a patient will usually have more than one:
| Study | What it shows | Where it fits |
|---|---|---|
| Radionuclide bone scan | Areas of increased bone turnover across the whole skeleton | The usual first survey, because it looks at the entire body in one study; interpreted with the history, since fractures and arthritis also take up the tracer |
| PET-CT | The activity of the cancer itself, together with the structure of the bone | Used where the extent of disease elsewhere matters, and where a deposit needs to be distinguished from a benign cause |
| CT | The fine structure of the bone — how much has been destroyed, and the risk of fracture | The study that answers whether a load-bearing bone needs stabilising, and the one used to plan surgery |
| MRI | The bone marrow, the spinal cord and the nerve roots | Done urgently when there is back pain with weakness, numbness or bladder and bowel change, because it shows the cord directly |
| Plain radiographs | Bone that has already lost enough density to be visible | Quick and useful for a specific painful site, though they miss deposits that have not yet thinned the bone |
A normal bone scan does not exclude a deposit, and an abnormal one does not confirm it. A bone scan reflects bone turnover rather than cancer, so a healing fracture or arthritis can look identical, while a deposit that provokes little reaction around it can be missed altogether — which is why the scan is read alongside the history and the targeted imaging rather than on its own. Where the cancer is already known and the PET-CT appearance is typical, no further confirmation is usually needed and the process moves on to planning. In a patient with no known cancer, the same finding starts a search for the primary tumour.
When a sample of the deposit is taken
Bone metastasis is confirmed by showing that a deposit contains cells of the original cancer. Where the primary tumour is already known and the imaging is characteristic, that confirmation may already be present and no further procedure is needed. Where it is not, a biopsy of the deposit is taken.
The sample is usually taken with a needle, under imaging guidance, and often under local anaesthetic with sedation. A radiologist uses CT or ultrasound to place the needle accurately into the part of the deposit that is most likely to yield a diagnosis — the soft tissue component rather than the dense bone. It is a short procedure, and the main reason to plan it carefully is that a deposit that is mostly sclerotic bone can be unrewarding to sample, so the choice of the target within the lesion matters as much as the technique.
The biopsy answers three questions. Whether the deposit contains cancer cells at all, whether those cells match the known primary tumour, and whether the markers that guide treatment have changed. The last of these is why a biopsy is sometimes taken from a deposit even when the primary is known: a cancer can alter its receptor status or its driver mutation over time or after treatment, and the alteration can change which drugs are used. Where that possibility exists, re-sampling is a deliberate step rather than a diagnostic afterthought.
When the cancer has not been diagnosed before
Occasionally a bone deposit is the first sign of a cancer that has not been found. This situation — a bone lesion in someone with no known primary tumour — changes the order of the assessment, because the question is no longer only what the deposit is, but where it came from.
The biopsy is then the key step, because the pattern of the cells, together with a panel of markers, usually points to the organ of origin: the appearance of the tissue, and markers such as hormone receptors, HER2, thyroid transcription factor, PSA and others, narrow the possibilities considerably. Imaging is used in parallel — a CT of the chest, abdomen and pelvis, and often a PET-CT — to look for the primary tumour itself and for disease elsewhere.
Even when the primary tumour is never found, treatment can still be given. In a proportion of patients the origin of the deposit cannot be established, and treatment is then guided by the markers in the tissue and by the pattern of spread. In that situation a specialist review of the pathology — and sometimes a second opinion on the tissue itself — has real value, because the treatment rests on an inference about where the cancer came from, and that inference is worth more than one pair of eyes.
Mapping how much bone is involved
Once a deposit is identified, the next question is how much of the skeleton is involved and whether any part of it is at risk. That description is what the treatment is built on, and it is recorded systematically rather than impressionistically:
- Which bones — the spine at which level, the pelvis, the ribs, the upper femur, the skull, or elsewhere.
- How many — one deposit, a limited number, or widespread involvement of the skeleton, since that decides whether local treatment is even relevant.
- What type — dissolving, dense, or mixed, which affects both the appearance on scans and the mechanical strength of the bone.
- Structural risk — how much of a load-bearing bone has been destroyed, which is the question that determines whether stabilising surgery should be planned before a fracture.
- Relation to the cord and roots — whether any vertebral deposit touches or compresses the spinal cord or a nerve root, which is answered by MRI rather than assumed from the site of the pain.
- Disease elsewhere — the state of the cancer in other organs, since bone is treated alongside the rest of the disease rather than in isolation.
Blood tests: what they add that imaging cannot
Blood tests do not diagnose bone metastasis on their own, but they answer questions that imaging cannot, and two of them are the basis for treating complications before they become emergencies:
| Test | What it reflects | Why it is done |
|---|---|---|
| Calcium (corrected) | Whether bone breakdown has raised the calcium in the blood | A raised level is an emergency that is corrected with fluids and medication, and it is monitored during treatment |
| Alkaline phosphatase | Activity of bone-forming cells, which rises where deposits are active | Useful as a baseline and for following the disease over time, though it is not specific and has other causes |
| Kidney function | How well the kidneys are working | Checked before and during bone-modifying drugs, since both the drugs and a raised calcium level affect the kidneys |
| Full blood count | Whether the marrow is affected | Important because the bone marrow is where blood cells are made, and widespread involvement can affect the counts |
| Tumour markers and hormones | Markers relevant to the original cancer — PSA, CA 15-3, and others | Used to follow the disease where they are informative, and never as a substitute for imaging |
| Vitamin D and phosphate | Whether the minerals needed for bone health are adequate | Corrected where low, because they affect the risk of further bone problems during treatment |
A calcium result should not be treated as a routine number. The drowsiness, confusion, thirst and nausea that a raised calcium level causes are easily attributed to the cancer itself, and yet they are entirely treatable the moment they are recognised. This is why patients starting a bone-modifying drug are told to report those symptoms rather than assume they are part of the illness. Blood is checked at intervals during treatment not because the disease can be measured in it, but because the complications and the side effects of treatment can.
How the picture becomes a plan
The diagnosis is complete when the imaging has mapped the deposits, the pathology has established what the cancer is, and the blood tests have shown whether the calcium and kidney function allow the drugs that protect the skeleton. Those findings are then reviewed together, because the treatment of a bone deposit depends on both what the deposit is doing and what the underlying cancer is.
The two halves of the plan are made at the same time. The systemic half — hormonal treatment, targeted therapy, chemotherapy or immunotherapy — is chosen by the pathology of the original cancer. The local half — radiotherapy, surgery, cement, or pain treatment — is chosen by what each deposit is doing to the bone. A patient may need both, and the order in which they are given is a decision in its own right: a deposit that threatens the cord is treated before anything else, whereas several deposits that are not causing trouble can wait while the systemic treatment takes effect.
Bring the material that makes the assessment possible: the original pathology report in full, with the receptor and marker results; the bone imaging with its reports and dates; the record of treatment already given for the original cancer; the most recent blood results; and the complete current medication list including pain relief. With those in hand, the review is a judgement made on real material rather than an opinion passed on a summary — and the written assessment is returned within 48 hours of the file being complete.